Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes

scientific article

Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.2174/1381612013397401
P698PubMed publication ID11472275

P2093author name stringD J Drucker
P433issue14
P304page(s)1399-1412
P577publication date2001-09-01
P1433published inCurrent Pharmaceutical DesignQ5195068
P1476titleDevelopment of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes
P478volume7

Reverse relations

cites work (P2860)
Q42686673A New Paradigm for Protein Design and Biological Self-Assembly
Q37404417A cell-based approach for diabetes treatment using engineered non-beta cells
Q38323074A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Q36567296An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes
Q33559925CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies
Q46209442Changes in satiety hormones and expression of genes involved in glucose and lipid metabolism in rats weaned onto diets high in fibre or protein reflect susceptibility to increased fat mass in adulthood
Q46397532Chronic inhibition of dipeptidyl peptidase-IV with ASP8497 improved the HbA(1c) level, glucose intolerance, and lipid parameter level in streptozotocin-nicotinamide-induced diabetic mice
Q36892807Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus
Q58864229Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes
Q37468406Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin
Q45242151GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats
Q38089183GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity
Q24653673GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity
Q38033468Glucagon-like peptide-1 and its cardiovascular effects
Q42557469Glucagon-like peptide-1 functionalized PEG hydrogels promote survival and function of encapsulated pancreatic beta-cells
Q46278128Glucagon-like peptide-1 in the rat brain: distribution of expression and functional implication
Q34786386Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy
Q38345800Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway
Q37306253Glucose tolerance, lipids, and GLP-1 secretion in JCR:LA-cp rats fed a high protein fiber diet
Q46632337In vivo biological activity of exendin (1-30).
Q34374336Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors
Q43177381Influence of selective fluorination on the biological activity and proteolytic stability of glucagon-like peptide-1.
Q43196000Molecular docking and 3D-QSAR studies on beta-phenylalanine derivatives as dipeptidyl peptidase IV inhibitors
Q27005992Neural control of energy balance: translating circuits to therapies
Q38398676Novel hydrazine derivatives as selective DPP-IV inhibitors: findings from virtual screening and validation through molecular dynamics simulations.
Q37365702Personalized pharmacotherapy for Type 2 diabetes mellitus
Q37142047Pharmacogenetics: potential role in the treatment of diabetes and obesity
Q52725083Position-dependent impact of hexafluoroleucine and trifluoroisoleucine on protease digestion.
Q34977231Preclinical developments in type 2 diabetes
Q35175990RANTES (CCL5) reduces glucose-dependent secretion of glucagon-like peptides 1 and 2 and impairs glucose-induced insulin secretion in mice
Q73141458The intriguing diversity of the glucagon gene products
Q34648201Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

Search more.